Nurix Therapeutics (NRIX)
(Delayed Data from NSDQ)
$8.44 USD
-0.53 (-5.91%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $8.42 -0.02 (-0.24%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NRIX 8.44 -0.53(-5.91%)
Will NRIX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NRIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NRIX
KalVista Pharmaceuticals, Inc. (KALV) Reports Q1 Loss, Lags Revenue Estimates
Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
NRIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Predict a 143.41% Upside in Nurix Therapeutics (NRIX): Here's What You Should Know
Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?
Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates
Other News for NRIX
Technical picture remains unchanged for NRIX after it falls 5.91% on September 20
NRIX forms Stochastic Buy Signal on September 18
Pocket Pivot appears for NRIX after 1.54% move
Nurix Therapeutics (NRIX) Receives a Buy from Stifel Nicolaus
Nurix Therapeutics (NRIX) Gets a Buy from Barclays